An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

Conditions

• Relapsing Multiple Sclerosis

Interventions

• BIOLOGICAL: Ofatumumab

Sponsor

Novartis Pharmaceuticals